GlassScriptPhysician profile
Megan Cuff
NPI 1649891375
$1,044.04
in general payments reported to CMS, 2019-2025
30 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $498 · 2023: $20.33 · 2024: $70.79 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $153.12 | 2025 | Intellis Adaptivestim |
| Seagen INC. | $115.69 | 2022 | |
| Abbvie INC. | $58.80 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $53.27 | 2021-2022 | |
| Orthofix Medical, INC. | $51.74 | 2024 | Spinal-Stim, Cervical-Stim |
| Coherus Oncology, INC. | $41.39 | 2022 | |
| Amag Pharmaceuticals, INC. | $39.46 | 2021-2022 | |
| Pfizer INC. | $37.04 | 2021-2022 | |
| Adc Therapeutics America, INC. | $35.74 | 2022 | |
| Puma Biotechnology, INC. | $35.29 | 2021 | |
| Incyte Corporation | $34.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $33.22 | 2021-2022 | |
| Blueprint Medicines Corporation | $33.07 | 2021 | |
| Glaxosmithkline, LLC. | $32.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.51 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emmaus Medical, INC. | $24.48 | 2021 | |
| Daiichi Sankyo INC. | $22.47 | 2021 | |
| Myovant Sciences INC. | $20.65 | 2022 | |
| Genzyme Corporation | $20.26 | 2021 | |
| Exelixis INC. | $19.51 | 2022 | |
| Dynasplint Systems INC. | $19.05 | 2024 | Dynasplint |
| Celgene Corporation | $18.96 | 2022 | |
| Beigene USA, INC. | $17.24 | 2022 | |
| Acrotech Biopharma INC. | $16.02 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.87 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.45 | 2021 | |
| Lilly USA, LLC | $14.00 | 2021 | |
| Global Blood Therapeutics, INC. | $13.38 | 2022 | |
| Emd Serono, INC. | $13.25 | 2021 | |
| Janssen Biotech, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Cuff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.